<DOC>
	<DOCNO>NCT02974153</DOCNO>
	<brief_summary>The purpose study assess efficacy safety ALD403 prevention migraine headache chronic migraineurs .</brief_summary>
	<brief_title>Evaluation ALD403 ( Eptinezumab ) Prevention Chronic Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Males females 18 65 year age , inclusive , diagnosed migraine ≤ 50 year age , history chronic migraine ≥ 12 month screen . During 28 day screen period , subject must adequately complete headache eDiary must headaches occur ≥ 15 ≤ 26 day least 8 must migraine day . Headache eDiary complete least 24 28 day prior randomization . Confounding clinically significant pain syndrome ( e.g . fibromyalgia , chronic low back pain , complex regional pain syndrome ) . Psychiatric condition uncontrolled and/or untreated , include condition control minimum 6 month prior screen . Patients lifetime history psychosis , mania , dementia exclude . Any use botulinum toxin migraine medical/cosmetic reason require injection within 4 month prior screen screen period . History diagnosis complicate migraine ( ICHDIII beta version , 20134 ) , chronic tensiontype headache , hypnic headache , cluster headache , hemicrania continuum , new daily persistent headache , sporadic familial hemiplegic migraine . Receipt monoclonal antibody treatment ( within outside clinical trial ) within 6 month screen . Previously dose ALD403 monoclonal antibody target CGRP pathway .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>